237 related articles for article (PubMed ID: 26317598)
21. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
22. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M;
J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741
[TBL] [Abstract][Full Text] [Related]
23. Long-term survival in primary CNS lymphoma.
Abrey LE; DeAngelis LM; Yahalom J
J Clin Oncol; 1998 Mar; 16(3):859-63. PubMed ID: 9508166
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
26. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
[TBL] [Abstract][Full Text] [Related]
27. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
[TBL] [Abstract][Full Text] [Related]
28. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
[TBL] [Abstract][Full Text] [Related]
30. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G
Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743
[TBL] [Abstract][Full Text] [Related]
31. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
[TBL] [Abstract][Full Text] [Related]
32. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
33. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
Kiefer T; Krüger WH; Montemurro M; Schüler F; Hirt C; Pasold R; Niederwieser D; Schwenke M; Dölken G
Transfusion; 2008 Dec; 48(12):2624-8. PubMed ID: 18801020
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
36. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
37. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
38. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy.
Moulignier A; Lamirel C; Picard H; Lebrette MG; Amiel C; Hamidi M; Polivka M; Mikol J; Cochereau I; Pialoux G
Neurology; 2017 Aug; 89(8):796-804. PubMed ID: 28747447
[TBL] [Abstract][Full Text] [Related]
39. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
Salamoon M; Hussein T; Kenj M; Bachour M
Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
[TBL] [Abstract][Full Text] [Related]
40. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
